Ar­cutis' for­mu­la­tion of old As­traZeneca drug clears an­oth­er PhI­II test

Weeks af­ter rolling out its first pso­ri­a­sis treat­ment, Ar­cutis Bio­ther­a­peu­tics is rack­ing up more pos­i­tive Phase III da­ta for a sec­ond for­mu­la­tion of an old As­traZeneca drug.

The Phase III AR­REC­TOR tri­al test­ed rof­lu­mi­last foam in pa­tients with scalp and body pso­ri­a­sis, Ar­cutis said, and met both co-pri­ma­ry end­points as well as all sec­ondary end­points. Near­ly iden­ti­cal to its ap­proved drug, Zo­ryve, which is a cream, the foam is wa­ter-based and mois­tur­iz­ing — prop­er­ties that the biotech hoped could “over­come the chal­lenges of de­liv­er­ing top­i­cal drugs in hair-bear­ing ar­eas of the body.” Ar­cutis has pre­vi­ous­ly com­pared it to hair mousse.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER